Black Diamond Therapeutics, Inc. BDTX

1.88 (0.02) (1.05%) as of 25 Sep
Market cap
$108.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
8.72 8.18 8.14 6.98
Current Ratio
8.94 8.42 8.46 7.28
Net Debt/EBITDA
12.44 7.33 10.53 9.19
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.92 0.45 1.13 0.80
Capex/Depreciation
0.01 0.05 0.00 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.14) (0.12) (0.18) (0.14)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.14) (0.12) (0.18) (0.14)
Cash per Share
2.38 2.26 2.07 1.93
Shareholders Equity per Share
2.22 1.97 1.82 1.68
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.22 1.97 1.82 1.68
Free Cash Flow
(7.85) (6.78) (10.23) (7.97)
Working Capital
123.45 116.71 108.43 99.55
Capital Expenditures
0.00 0.00 — —
Net Current Asset Value
107.41 101.64 94.35 86.46
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 — —
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Payables
1.47 2.29 2.80 1.09
Average Assets
147.81 132.83 154.58 145.71
Average Common Equity
111.79 97.75 122.91 114.35

Fold the line items

Columns are period end dates